Related references
Note: Only part of the references are listed.Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
Paul M. Ridker et al.
LANCET (2018)
Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions
Paolo Raggi et al.
ATHEROSCLEROSIS (2018)
Brusatol overcomes chemoresistance through inhibition of protein translation
Bryan Harder et al.
MOLECULAR CARCINOGENESIS (2017)
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
P. M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Brusatol-Mediated Inhibition of c-Myc Increases HIF-1α Degradation and Causes Cell Death in Colorectal Cancer under Hypoxia
Eun-Taex Oh et al.
THERANOSTICS (2017)
Application of Mass Spectrometry Profiling to Establish Brusatol as an Inhibitor of Global Protein Synthesis
Steffan Vartanian et al.
MOLECULAR & CELLULAR PROTEOMICS (2016)
NQO1 inhibits proteasome-mediated degradation of HIF-1α
Eun-Taex Oh et al.
NATURE COMMUNICATIONS (2016)
Brusatol Enhances the Radiosensitivity of A549 Cells by Promoting ROS Production and Enhancing DNA Damage
Xiaohui Sun et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Atherosclerosis: a chronic inflammatory disease mediated by mast cells
Pio Conti et al.
CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY (2015)
Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity-implications for therapeutic targeting of Nrf2
Adedamola Olayanju et al.
FREE RADICAL BIOLOGY AND MEDICINE (2015)
Oncogenic KRAS Confers Chemoresistance by Upregulating NRF2
Shasha Tao et al.
CANCER RESEARCH (2014)
Targeting inflammatory pathways for the treatment of cardiovascular disease
Paul M. Ridker
EUROPEAN HEART JOURNAL (2014)
Endothelial Dysfunction in Chronic Inflammatory Diseases
Curtis M. Steyers et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2014)
Novel Nitric Oxide-Releasing Derivatives of Brusatol as Anti-Inflammatory Agents: Design, Synthesis, Biological Evaluation, and Nitric Oxide Release Studies
Weibin Tang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Inflammatory therapeutic targets in coronary atherosclerosis - from molecular biology to clinical application
Fabian Linden et al.
FRONTIERS IN PHYSIOLOGY (2014)
Animal Models of Atherosclerosis
Godfrey S. Getz et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism
Dongmei Ren et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Partial carotid ligation is a model of acutely induced disturbed flow, leading to rapid endothelial dysfunction and atherosclerosis
Douglas Nam et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2009)
Role for TNF in atherosclerosis? Lessons from autoimmune disease
Gayle E. McKellar et al.
NATURE REVIEWS CARDIOLOGY (2009)
Absence of p55 TNF Receptor Reduces Atherosclerosis, but Has No Major Effect on Angiotensin II Induced Aneurysms in LDL Receptor Deficient Mice
Sofia Xanthoulea et al.
PLOS ONE (2009)
The NF-κB Family of Transcription Factors and Its Regulation
Andrea Oeckinghaus et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2009)
Monocyte-Endothelial Cell Interactions in the Development of Atherosclerosis
Javier Mestas et al.
TRENDS IN CARDIOVASCULAR MEDICINE (2008)
Expression of tumor necrosis factor receptor-1 in arterial wall cells promotes atherosclerosis
Lisheng Zhang et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Inhibition of TNF receptor 1 internalization by adenovirus 14.7K as a novel immune escape mechanism
Wulf Schneider-Brachert et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Rab proteins, connecting transport and vesicle fusion
I Jordens et al.
TRAFFIC (2005)
Disruption of tumor necrosis factor-α gene diminishes the development of atherosclerosis in ApoE-deficient mice
H Ohta et al.
ATHEROSCLEROSIS (2005)
Mechanisms of disease - Inflammation, atherosclerosis, and coronary artery disease
GK Hansson
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Tumor necrosis factor-α promotes atherosclerotic lesion progression in APOE*3-leiden transgenic mice
LSM Boesten et al.
CARDIOVASCULAR RESEARCH (2005)
Molecular mechanisms of translational control
F Gebauer et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
Translation initiation: structures, mechanisms and evolution
A Marintchev et al.
QUARTERLY REVIEWS OF BIOPHYSICS (2004)
Inhibition of tumor necrosis factor-α reduces atherosclerosis in apolipoprotein E knockout mice
L Branén et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Inflammation and atherosclerosis
P Libby et al.
CIRCULATION (2002)
Gene-specific regulation by general translation factors
TE Dever
CELL (2002)
Tight binding of the phosphorylated α subunit of initiation factor 2 (eIF2α) to the regulatory subunits of guanine nucleotide exchange factor eIF2B is required for inhibition of translation initiation
T Krishnamoorthy et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Share Paper
